Literature DB >> 29251415

Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.

Helena M Bijen1, Chopie Hassan2, Michel G D Kester1, George M C Janssen2, Pleun Hombrink1, Arnoud H de Ru2, Jan Wouter Drijfhout2, Hugo D Meiring3, Ad P de Jong3, J H Frederik Falkenburg1, Connie R Jimenez4, Mirjam H M Heemskerk1, Peter A van Veelen2.   

Abstract

Allogeneic stem cell transplantation has emerged as immunotherapy in the treatment of a variety of hematological malignancies. Its efficacy depends on induction of graft versus leukemia by donor lymphocytes. Both graft versus leukemia and graft versus host disease are induced by T cells reactive against polymorphic peptides, called minor histocompatibility antigens (MiHA), which differ between patient and donor and are presented in the context of self-HLA (where HLA is human leukocyte antigen). The allelic counterpart (AC) of the MiHA is generally considered to be absent at the cell surface, based on the absence of immune responses directed against the AC. To study this in detail, we evaluate the recognition, HLA-binding affinity, and cell surface expression of three selected MiHA. By quantitative MS, we demonstrate the similarly abundant expression of both MiHA and AC at the cell surface. We conclude that the absent recognition of the AC cannot generally be explained by insufficient processing and presentation at the cell surface of the AC.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  MRM/SRM; MS-LC-MS/MS; T cell immunology; immunoproteomics; leukaemia/lymphoma; peptidomics; stable isotope labeling

Mesh:

Substances:

Year:  2018        PMID: 29251415     DOI: 10.1002/pmic.201700250

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  7 in total

1.  The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.

Authors:  Juan Antonio Vizcaíno; Peter Kubiniok; Kevin A Kovalchik; Qing Ma; Jérôme D Duquette; Ian Mongrain; Eric W Deutsch; Bjoern Peters; Alessandro Sette; Isabelle Sirois; Etienne Caron
Journal:  Mol Cell Proteomics       Date:  2019-11-19       Impact factor: 5.911

2.  Rapid Multiplex Genotyping of 20 HLA-A*02:01 Restricted Minor Histocompatibility Antigens.

Authors:  Dmitrii S Romaniuk; Anna M Postovskaya; Alexandra A Khmelevskaya; Dmitry B Malko; Grigory A Efimov
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 3.  Typical and atypical properties of peripheral nerve allografts enable novel strategies to repair segmental-loss injuries.

Authors:  George D Bittner; Jared S Bushman; Cameron L Ghergherehchi; Kelly C S Roballo; Jaimie T Shores; Tyler A Smith
Journal:  J Neuroinflammation       Date:  2022-02-28       Impact factor: 8.322

4.  Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.

Authors:  Lukas Jac Hawinkels; Els Me Verdegaal; Tom J Harryvan; Marten Visser; Linda de Bruin; Léonie Plug; Lisa Griffioen; Arend Mulder; Peter A van Veelen; Gerbrand J van der Heden van Noort; Marlieke Lm Jongsma; Miranda H Meeuwsen; Emmanuel Jhj Wiertz; Saskia J Santegoets; James Ch Hardwick; Thorbald Van Hall; Jacques Neefjes; Sjoerd H Van der Burg
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

Review 5.  The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction.

Authors:  Tuna Mutis; Anastasia Xagara; Robbert M Spaapen
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

6.  In Silico Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project.

Authors:  Nadia A Bykova; Dmitry B Malko; Grigory A Efimov
Journal:  Front Immunol       Date:  2018-08-16       Impact factor: 7.561

7.  Are There Indeed Spliced Peptides in the Immunopeptidome?

Authors:  Arie Admon
Journal:  Mol Cell Proteomics       Date:  2021-05-20       Impact factor: 5.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.